Management of Etonogestrel Subdermal Implant-related Bleeding

Completed · Phase 3 · Has a placebo group

Conditions studied: ESI-related Bleeding

In brief

This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (ESI), as compared to placebo.

Key facts

Study ID

NCT01658995

Run by

Petra M. Casey

People needed

82

Starts

2012-09-13

Expected to finish

2019-12-30

Last updated by the study team

2021-01-26

Who can join

Age: 18 and older, up to 51. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Premenopausal women, aged 18-51 years
• Expressed desire for compliance-independent contraception
• No current pregnancy or anticipated desire for childbearing within 3 years of study enrollment and Implanon insertion
• Agreement to participate in all study related procedures and evaluations as documented by a signed informed consent

You may not qualify if…

• Current or prior use of Implanon
• Current long-term use of Doxycycline for other indications
• Known structural uterine abnormalities such as polyp, submucosal leiomyoma
• Prior permanent sterilization or endometrial ablation
• Pregnancy or desire for childbearing within 3 years
• Contraindications to or intolerance of etonogestrel
• Allergy to or intolerance of Doxycycline
• Inability or unwillingness to complete study related procedures and evaluations

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.